Summary
- Profile Type
- Technology offer
- POD Reference
- TODE20250214011
- Term of Validity
- 14 February 2025 - 14 February 2026
- Company's Country
- Germany
- Type of partnership
- Investment agreement
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The invention of a German university provides a reproducible method of producing ASA-nicotinic acid amide co-crystals with improved solubilty and bioavailability. The invention is available for licensing and further development together with the researchers of university.
- Full Description
-
Acetylsalicylic acid (ASA) is one of the most prescribed non-steroidal anti-inflammatory drugs. ASA has an analgesic, anti-inflammatory and antipyretic effect and prevents platelet aggregation. Due to its effects on blood clotting, ASA is also used for cardiovascular prophylaxis and to prevent strokes in high-risk patients.
A significant technical disadvantage of ASA is its very low water solubility. In order to solve this problem, many research groups and companies have been working for a long time on the question of how to improve the water solubility of ASA and thus also its absorption and bioavailability.
The invention of a German university provides a reproducible method of producing ASA-nicotinic acid amide co-crystals with improved solubilty and bioavailability.
The invention is available for licensing and further development together with the researchers of university. This offer is of interest to companies in the pharmaceutical industry. - Advantages and Innovations
-
The main advantge of this invention is the improved ASA solbility. Ohter advantages are:
- Reproducible synthesis method
- Well characterized co-crystals - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- A patent has been filed with the European Patent Office.
Partner Sought
- Expected Role of a Partner
- The invention is available for licensing and further development together with the researchers of university. This offer is of interest to companies in the pharmaceutical industry.
- Type and Size of Partner
- SME <=10
- Big company
- SME 50 - 249
- Other
- SME 11-49
- Type of partnership
- Investment agreement
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001015 - Pharmaceutical Products / Drugs
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- Targeted countries
- All countries
